Sermorelin is not an FDA-approved adult weight-loss GLP-1

Geref's actual job, and why it left the market

Sermorelin is a 29-amino-acid analog of the N-terminal sequence of human growth hormone-releasing hormone. Under the brand Geref it was FDA-approved for diagnosing growth-hormone deficiency and for treating idiopathic GH deficiency in children with growth failure. In 2008, EMD Serono discontinued the products. FDA withdrew the NDAs in 2009. A 2013 Federal Register notice later confirmed the discontinuation was not because the agency found the products unsafe or ineffective. Commercial demand and manufacturing, not a toxicity scandal, ended branded supply.

This page is educational, not medical advice. Beema Health does not offer sermorelin today and does not advertise it as a fat-loss peptide.

Why adult fat-loss marketing overreaches

Growth hormone affects body composition, which is why wellness clinics retell sermorelin as a lean-mass shot. That leap skips the evidence standard used for modern obesity drugs: large randomized trials with percent weight change, cardiometabolic endpoints, and labeled risk language. Sermorelin never had a Wegovy-style obesity indication. Hype for unapproved fat-loss use is exactly what this article will not repeat as a benefit claim.

If an adult has documented growth-hormone deficiency, recombinant growth hormone - not a discontinued diagnostic peptide - is the usual labeled therapy. That diagnosis is specialized. Beema's weight-loss intake is not an endocrine stimulation-test clinic.

Sermorelin versus GLP-1-class medicines

GLP-1 receptor agonists reduce energy intake through gut-brain signaling. Sermorelin tries to raise pituitary growth-hormone pulses. Side-effect profiles differ. Glucose, edema, carpal-tunnel symptoms, and IGF-1 excess are growth-hormone-axis concerns. Nausea and delayed gastric emptying are incretin-axis concerns. Mixing the two in a 'peptide stack' without a clinician is unsafe amateur pharmacology.

• Sermorelin: GHRH analog, historic pediatric GH use, no current FDA-approved U.S. brand
• Tesamorelin: related axis, but a different molecule with a current HIV lipodystrophy label
• Semaglutide/tirzepatide: incretin agonists with obesity-trial evidence Beema may evaluate as compounded options

Compounded and research-chemical sermorelin

After Geref left the market, compounding pharmacies and internet vendors filled the gap. Compounded sermorelin is not FDA-approved as a finished drug. Research-labeled vials are not medicines. Beema will not sell either. Prescription status does not disappear because a website uses the word peptide.

Athletes should also know that growth-hormone releasing factors are prohibited in sport under WADA rules. That is another reason this is not a casual wellness add-on.

Safety issues this page will not minimize

Stimulating growth hormone can raise IGF-1. People with active malignancy, uncontrolled diabetes, or untreated pituitary disease need specialist judgment before any GH-axis drug. Injection-site reactions occur. Long-term adult wellness dosing has a thin evidence file compared with incretin obesity trials. Absence of a 2008 safety withdrawal is not proof that off-label adult fat-loss use is wise.

What Beema Health will discuss instead

Beema offers cash-pay telehealth for medical weight loss in all 50 U.S. states. Licensed providers may prescribe compounded semaglutide or compounded tirzepatide when legally available and clinically appropriate. Compounded semaglutide is not FDA-approved. Compounded tirzepatide is not FDA-approved. Completing intake never guarantees a prescription.

If a social ad promised sermorelin as a gentler Ozempic, that comparison is false on mechanism and false on evidence. Read GLP-1 education next, or the tesamorelin article if you need the other GHRH analog's labeled indication.

Frequently asked questions

Sources

1. [1] Federal Register. Determination that GEREF (sermorelin acetate) products were not withdrawn from sale for reasons of safety or effectiveness. March 4, 2013.
2. [2] Federal Register. Withdrawal of approval of GEREF NDAs 19-863 and 20-443 (effective June 18, 2009), following manufacturer discontinuation.
3. [3] EGRIFTA WR (tesamorelin) label, for contrast: a different GHRH analog with a current FDA indication that still is not general weight loss.
4. [4] NIDDK. Prescription medications to treat overweight and obesity.